PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
ClinVar Genomic variation as it relates to human health
NC_000019.10:g.39248147C>T
Germline
Somatic
No data submitted for somatic clinical impact
Somatic
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NC_000019.10:g.39248147C>T
Variation ID: 225949 Accession: VCV000225949.4
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 19q13.2 19: 39248147 (GRCh38) [ NCBI UCSC ] 19: 39738787 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Apr 9, 2018 Dec 12, 2021 Mar 24, 2021 - HGVS
-
... more HGVS ... less HGVSNucleotide Protein Molecular
consequenceNM_001276254.2:c.151-152G>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NC_000019.10:g.39248147C>T NC_000019.9:g.39738787C>T NG_042193.1:g.1825G>A NG_055295.1:g.5710G>A LRG_1011:g.1825G>A - Protein change
- -
- Other names
- -
- Canonical SPDI
- NC_000019.10:39248146:C:T
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
-
0.35583 (T)
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
1000 Genomes Project 0.35583
1000 Genomes Project 30x 0.37180
The Genome Aggregation Database (gnomAD) 0.37827
Trans-Omics for Precision Medicine (TOPMed) 0.40683
- Links
Genes
| Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
|---|---|---|---|---|---|---|
| HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
| IFNL3 | - | - |
GRCh38 GRCh38 GRCh37 |
29 | 40 | |
| IFNL4 | - | - |
GRCh38 GRCh38 |
- | 3 | |
Conditions - Germline
| Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
|---|---|---|---|---|
| Benign (1) |
criteria provided, single submitter
|
Mar 9, 2018 | RCV000614473.9 | |
| drug response (1) |
reviewed by expert panel
|
Mar 24, 2021 | RCV000211184.12 | |
| drug response (1) |
reviewed by expert panel
|
Mar 24, 2021 | RCV000211399.12 | |
|
boceprevir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin response - Efficacy
|
drug response (1) |
reviewed by expert panel
|
Mar 24, 2021 | RCV001788072.10 |
Submissions - Germline
| Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
|---|---|---|---|---|---|
|
drug response
Drug-variant association: Efficacy
(Mar 24, 2021)
|
reviewed by expert panel
Method: curation
|
boceprevir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin response - Efficacy
Drug used for
Hepatitis C, Chronic
Affected status: yes
Allele origin:
germline
|
PharmGKB
Accession: SCV002031221.1
First in ClinVar: Dec 12, 2021 Last updated: Dec 12, 2021
Comment:
Drug is not necessarily used to treat response condition
|
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or … (more)
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. (less)
|
|
|
drug response
Drug-variant association: Efficacy
(Mar 24, 2021)
|
reviewed by expert panel
Method: curation
|
peginterferon alfa-2a, peginterferon alfa-2b and ribavirin response - Efficacy
Drug used for
Hepatitis C
Affected status: yes
Allele origin:
germline
|
PharmGKB
Accession: SCV000268184.4
First in ClinVar: May 22, 2016 Last updated: Dec 12, 2021
Comment:
Drug is not necessarily used to treat response condition
|
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or … (more)
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. (less)
|
|
|
drug response
Drug-variant association: Efficacy
(Mar 24, 2021)
|
reviewed by expert panel
Method: curation
|
peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir response - Efficacy
Drug used for
Hepatitis C, Chronic
Affected status: yes
Allele origin:
germline
|
PharmGKB
Accession: SCV000268185.4
First in ClinVar: May 22, 2016 Last updated: Dec 12, 2021
Comment:
Drug is not necessarily used to treat response condition
|
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or … (more)
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. (less)
|
|
|
Benign
(Mar 09, 2018)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000724151.1
First in ClinVar: Apr 09, 2018 Last updated: Apr 09, 2018 |
Comment:
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at … (more)
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. (less)
|
Comment:
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Comment:
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Germline Functional Evidence
| There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Comment:
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Citations for germline classification of this variant
Help| Title | Author | Journal | Year | Link |
|---|---|---|---|---|
| IFNL4 haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population. | Roy N | Virusdisease | 2019 | PMID: 31803800 |
| IL-28β gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients. | El-Khazragy N | Journal of cellular biochemistry | 2019 | PMID: 30450628 |
| The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. | Sakhaee F | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases | 2017 | PMID: 28739427 |
| EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. | Asnavandi M | Genes and immunity | 2017 | PMID: 28703131 |
| Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. | Bichoupan K | World journal of hepatology | 2017 | PMID: 28469811 |
| A systematic review and meta-analysis of HCV clearance. | Gauthiez E | Liver international : official journal of the International Association for the Study of the Liver | 2017 | PMID: 28261910 |
| Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population. | Huang P | Scientific reports | 2017 | PMID: 28186161 |
| IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. | Sedighimehr P | Archives of virology | 2017 | PMID: 27714501 |
| Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection. | Kamal AM | Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie | 2016 | PMID: 27833958 |
| The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors. | Nguyen LT | PloS one | 2016 | PMID: 27711230 |
| Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent. | Ranjan P | Indian journal of medical microbiology | 2016 | PMID: 27514956 |
| Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3? | Mansoor S | The Journal of general virology | 2016 | PMID: 27498543 |
| Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C. | El-Derany MO | BMC gastroenterology | 2016 | PMID: 26911666 |
| Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C. | Schwarz KB | Journal of pediatric gastroenterology and nutrition | 2016 | PMID: 26284539 |
| Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. | Cariani E | The pharmacogenomics journal | 2016 | PMID: 25918016 |
| Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4. | El-Bendary M | Hepato-gastroenterology | 2015 | PMID: 26902034 |
| Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. | Wiegand SB | PloS one | 2015 | PMID: 26699619 |
| Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. | About F | PloS one | 2015 | PMID: 26670100 |
| Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection. | Thanapirom K | PloS one | 2015 | PMID: 26339796 |
| IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. | Calisti G | SpringerPlus | 2015 | PMID: 26191484 |
| Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. | Doyle JS | Journal of viral hepatitis | 2015 | PMID: 26098993 |
| The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. | Holmes JA | Alimentary pharmacology & therapeutics | 2015 | PMID: 26032235 |
| The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C. | Nadia K | Gene | 2015 | PMID: 25958342 |
| Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals. | Sehgal M | Journal of clinical & cellular immunology | 2014 | PMID: 25705565 |
| Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. | Susser S | PloS one | 2014 | PMID: 25393304 |
| IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. | Rosso C | World journal of gastroenterology | 2014 | PMID: 25278709 |
| IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. | Eslam M | Journal of hepatology | 2014 | PMID: 24768758 |
| IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. | Real LM | PloS one | 2014 | PMID: 24748394 |
| The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. | Covolo L | Alimentary pharmacology & therapeutics | 2014 | PMID: 24308755 |
| Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. | Tsubota A | Journal of gastroenterology and hepatology | 2014 | PMID: 24117654 |
| Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. | Ragheb MM | Liver international : official journal of the International Association for the Study of the Liver | 2014 | PMID: 24102823 |
| IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. | Franco S | AIDS (London, England) | 2014 | PMID: 24072198 |
| Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. | García-Martín E | PloS one | 2013 | PMID: 24073221 |
| IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. | Bibert S | The Journal of experimental medicine | 2013 | PMID: 23712427 |
| Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. | Piluso A | Journal of viral hepatitis | 2013 | PMID: 23490377 |
| HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism. | Stenkvist J | Journal of viral hepatitis | 2013 | PMID: 23383658 |
| Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. | Pol S | Journal of hepatology | 2013 | PMID: 23321318 |
| A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. | Prokunina-Olsson L | Nature genetics | 2013 | PMID: 23291588 |
| Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. | Luo Y | Gene | 2013 | PMID: 23142377 |
| Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. | Riva E | Journal of viral hepatitis | 2012 | PMID: 22863269 |
| Factors that predict response of patients with hepatitis C virus infection to boceprevir. | Poordad F | Gastroenterology | 2012 | PMID: 22626609 |
| Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. | Kobayashi M | Journal of gastroenterology | 2012 | PMID: 22438096 |
| IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. | Antaki N | Gut | 2012 | PMID: 22345656 |
| Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. | de Castellarnau M | PloS one | 2012 | PMID: 22328925 |
| IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. | Asselah T | Journal of hepatology | 2012 | PMID: 21951981 |
| The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. | Sporea I | Hepatitis monthly | 2011 | PMID: 22368681 |
| Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. | Lopez-Rodriguez R | Clinical pharmacology and therapeutics | 2011 | PMID: 21993426 |
| IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. | Venegas M | World journal of gastroenterology | 2011 | PMID: 21987611 |
| Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. | Ridruejo E | Annals of hepatology | 2011 | PMID: 21911885 |
| Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. | Lyoo K | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology | 2011 | PMID: 21907615 |
| IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin. | Giannini EG | Alimentary pharmacology & therapeutics | 2011 | PMID: 21726252 |
| Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. | Lindh M | The Journal of infectious diseases | 2011 | PMID: 21606533 |
| Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. | Pineda JA | AIDS (London, England) | 2011 | PMID: 21572301 |
| Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. | Labarga P | AIDS (London, England) | 2011 | PMID: 21537116 |
| IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. | Rallón NI | AIDS (London, England) | 2011 | PMID: 21505315 |
| Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. | Coto-Llerena M | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | 2011 | PMID: 21466653 |
| Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. | Liao XW | Antiviral therapy | 2011 | PMID: 21447862 |
| Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. | Lagging M | PloS one | 2011 | PMID: 21390311 |
| IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. | Moghaddam A | Hepatology (Baltimore, Md.) | 2011 | PMID: 21374656 |
| IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. | Chen JY | Genes and immunity | 2011 | PMID: 21346780 |
| Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. | Darling JM | Hepatology (Baltimore, Md.) | 2011 | PMID: 21254158 |
| Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. | Suzuki F | Hepatology (Baltimore, Md.) | 2011 | PMID: 21246582 |
| Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. | de Araujo ES | Journal of acquired immune deficiency syndromes (1999) | 2011 | PMID: 21157362 |
| Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. | Scherzer TM | Journal of hepatology | 2011 | PMID: 21145807 |
| Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. | Sarrazin C | Journal of hepatology | 2011 | PMID: 21112657 |
| HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. | Hayes CN | Gut | 2011 | PMID: 21068134 |
| Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. | Stättermayer AF | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2011 | PMID: 20728570 |
| Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. | Medrano J | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2010 | PMID: 20964522 |
| IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. | Urban TJ | Hepatology (Baltimore, Md.) | 2010 | PMID: 20931559 |
| Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. | Pineda JA | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2010 | PMID: 20804372 |
| Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. | Akuta N | Hepatology (Baltimore, Md.) | 2010 | PMID: 20648473 |
| An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. | Mangia A | Gastroenterology | 2010 | PMID: 20621700 |
| Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. | Montes-Cano MA | Hepatology (Baltimore, Md.) | 2010 | PMID: 20578254 |
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. | Thompson AJ | Gastroenterology | 2010 | PMID: 20399780 |
| Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. | Rallón NI | AIDS (London, England) | 2010 | PMID: 20389235 |
| Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. | McCarthy JJ | Gastroenterology | 2010 | PMID: 20176026 |
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. | Ge D | Nature | 2009 | PMID: 19684573 |
| https://www.pharmgkb.org/clinicalAnnotation/1183680546 | - | - | - | - |
| https://www.pharmgkb.org/clinicalAnnotation/1183888969 | - | - | - | - |
| https://www.pharmgkb.org/clinicalAnnotation/827862764 | - | - | - | - |
| https://www.pharmgkb.org/variant/PA166155468 | - | - | - | - |
| click to load more click to collapse | ||||
Text-mined citations for rs12979860 ...
HelpThese citations are identified by LitVar using
the rs number, so they may include citations for more than one variant
at this location. Please review the LitVar results carefully for your
variant of interest.
Record last updated Nov 25, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.